Novo Nordisk Launches Phase III Trial of CagriSema for Obesity in China, Demonstrating Superiority Over Semaglutide

On July 5, the Drug Clinical Trial Registry and Information Disclosure Platform showed that Novo Nordisk registered a Phase III clinical trial (CTR20232030) in China comparing the dual-mechanism compound CagriSema with once-weekly semaglutide monotherapy for the treatment of overweight or obese patients.

Drug Clinical Trial Registration and Information Disclosure Platform

CagriSema Compound Contains Two Components: The Long-Acting Amylin (Amylin) Analog Cagrilintide and the Long-Acting GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Semaglutide. Amylin is another hormone related to hunger and satiety.

The trial is expected to enroll 300 participants, aiming to evaluate the safety and efficacy of subcutaneous CagriSema (2.4 mg/2.4mg) compared with placebo or once-weekly subcutaneous semaglutide.

Previously, the Phase II study of CagriSema for the treatment of type 2 diabetes yielded positive results. After using CagriSema, the average HbA1c of participants decreased by -2.18% from baseline, with 89% achieving the HbA1c target, demonstrating better blood sugar control than semaglutide alone.

Novo Nordisk Official Website

In addition to significantly reducing blood glucose levels in patients with type 2 diabetes, treatment with CagriSema led to an average weight loss of 15.6%, with more than half of the patients losing ≥15% of their body weight, surpassing the weight loss effects of semaglutide monotherapy.

Novo Nordisk Official Website

As early as the beginning of this year, Novo Nordisk registered a Phase III REDEFINE 3 study (NCT05669755) with 4,000 participants on the Clinicaltrials.gov website, aiming to investigate the impact of CagriSema injection on cardiovascular events, such as heart attacks and strokes, in patients with obesity and cardiovascular disease (see: ).

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon

↑ Click to scan the QR code and register for the live broadcast ↑